<DOC>
	<DOCNO>NCT01458730</DOCNO>
	<brief_summary>The purpose study test efficacy tolerability multiagent chemotherapy treatment regimen without radiotherapy patient newly diagnose lymphoma brain .</brief_summary>
	<brief_title>Nordic Study Newly Diagnosed Primary Central Nervous System ( CNS ) Lymphoma</brief_title>
	<detailed_description>The objective study 1 . To investigate efficacy safety high-dose methotrexate-based induction polychemotherapy regimen combine Rituximab intraspinal DepoCyte follow temozolomide maintenance treatment newly diagnose primary central nervous system lymphoma 2 . To assess long term outcome concern neurotoxicity</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Pathologically verify primary central nervous system lymphoma No prior PCNSL treatment . Patients treated steroid alone eligible No sign lymphoma outside CNS ECOG performance status 04 Age &gt; 17 &lt; 76 year Written inform consent patient guardian Cardiac failure &gt; 3 Pregnancy lactation . Women childbearing potential request use effective method contraception avoid pregnancy period entry study least 3 month last study medication Previous malignancy unless disease free least five year Active infection . Regarding tuberculosis , patient risk test latent TB accord local practice treat centre . Positive HIV status Organ transplantation Serious psychiatric illness Prior radiotherapy brain Concomitant antiinflammatory medication discontinue Creatinine clearance &lt; 60 ml/minute calculate Cockcroft Gault formula Peripheral blood count granulocytes &lt; 1.5 x 109L platelet &lt; 100 x 109L Serum bilirubin &gt; 1.5 time ASAT alkaline phosphatase &gt; 2 time upper limit normal . Known anaphylaxis IgEmediated hypersensitivity murine protein component Rituximab exclude patient Rituximab treatment , remain part study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>PCNSL</keyword>
	<keyword>Immunochemotherapy</keyword>
	<keyword>Intraspinal Depocyt</keyword>
	<keyword>Maintenance temozolomide</keyword>
</DOC>